Sangamo Therapeutics Stock Plummets 56% After Pfizer Ends Partnership
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 31 2024
0mins
Should l Buy TFC?
Source: Barron's
Sangamo Therapeutics Stock Decline: Sangamo Therapeutics' stock dropped 56% after Pfizer withdrew from their collaboration to develop a hemophilia drug, despite positive trial results for the treatment.
Future Plans and Analyst Reactions: Sangamo plans to seek new partnerships to advance the hemophilia program while analysts expressed disappointment over the termination of the agreement but maintained a Buy rating on the stock.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TFC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TFC
Wall Street analysts forecast TFC stock price to rise
17 Analyst Rating
10 Buy
6 Hold
1 Sell
Moderate Buy
Current: 49.550
Low
50.00
Averages
55.93
High
64.00
Current: 49.550
Low
50.00
Averages
55.93
High
64.00
About TFC
Truist Financial Corporation is a financial services company. As a commercial bank, it offers a range of products and services through its wholesale and consumer businesses, including consumer and small business banking, commercial banking, corporate and investment banking, wealth management, payments, and specialized lending businesses. Its segments include Consumer and Small Business Banking (CSBB) and Wholesale Banking (WB). CSBB segment serves retail, premier, and small business clients, providing transaction, money market, savings, time deposits and payment services, credit cards, loans, and mortgages through digital banking, a network of community banking branches, ATMs, virtual service centers, and other channels. WB segment provides a comprehensive set of products, solutions, and advisory services to commercial, corporate, institutional and wealth clients. It also invests in certain affordable housing, new market tax credit, and renewable energy tax credit investments.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Truist Initiates Buy Rating on Toll Brothers with $190 Price Target
- Investment Rating Upgrade: Truist has initiated a buy rating on Toll Brothers with a $190 price target, indicating a 24% upside, reflecting strong market confidence in the company.
- Market Positioning Advantage: Analysts highlight that Toll Brothers' focus on the luxury home market differentiates it from competitors, and its higher price point has helped it achieve category leader status, suggesting continued stable performance.
- Future Growth Potential: Analysts believe that Toll Brothers will benefit from a rebound in the luxury home market in 2027, and its limited competition compared to low-end builders showcases its unique position in the market.
- Strong Stock Performance: Toll Brothers' shares have risen 14% this year and 42% over the past 12 months, indicating investor recognition of its long-term growth potential, especially amid the structural undersupply of homes in the U.S.
See More
BeOne Medicines AG Raises 2026 Revenue Guidance Amid Strong Q4 Results
- Significant Revenue Growth: BeOne Medicines AG reported global revenues of $1.5 billion for Q4 2025, reflecting a 33% increase from the previous quarter, while projecting $5.3 billion for 2026, a 40% year-over-year growth, indicating strong market performance and growth potential.
- Strong Brukinsa Performance: The company's lymphoma and leukemia treatment, Brukinsa, generated revenues of $1.1 billion and $3.9 billion for Q4 and the full year, respectively, marking increases of 38% and 49% from prior periods, further solidifying its market position in oncology.
- Analyst Price Target Increase: On February 27, Truist Securities raised its price target for BeOne Medicines AG from $400 to $412 while maintaining a Buy rating, reflecting confidence in the company's future growth, especially following the release of its fiscal 2026 revenue guidance.
- Market Expectation Pressure: Although the fiscal 2026 revenue guidance ranges from $6.2 billion to $6.4 billion, closely aligning with consensus estimates of $6.4 billion, analysts noted that this expectation has added pressure on the stock price, indicating a cautious market outlook on the company's future growth.
See More
Centene Named Among 14 Best GARP Stocks by Analysts
- Target Price Increase: Truist raised Centene's price target from $47 to $49 while maintaining a Buy rating, indicating analysts' optimism about the company's future growth, particularly after positive management meetings that highlighted confidence in profitability across various segments.
- Earnings Performance: In the Q4 2025 earnings report, Centene reported an adjusted diluted loss per share of $1.19; however, CEO Sarah London noted that the company slightly exceeded expectations shared in the third quarter, demonstrating resilience during a challenging year.
- Market Outlook: London anticipates that adjusted EPS for 2026 will exceed $3, representing over 40% year-over-year growth, which not only reflects stability in Medicaid and Marketplace segments but also indicates a rebuilding of the company's earnings strength.
- Business Diversification: Centene focuses on providing integrated services to government-sponsored and commercial healthcare programs, particularly for underinsured and uninsured individuals, with its diversified business model offering strong support for future growth.
See More
Nuvation Bio Expands SIGMA Study to Phase 3 Trial
- Clinical Trial Expansion: On February 9, Nuvation Bio announced a protocol amendment to the global SIGMA study, expanding it to a Phase 3 trial aimed at evaluating the efficacy of safusidenib for high-risk IDH1-mutant astrocytoma patients, highlighting the company's potential in oncology treatment.
- Expanded Patient Eligibility: The new protocol broadens patient eligibility in the registrational trial to include grades 2 and 3 IDH1-mutant astrocytoma patients with high-risk features, as well as grade 4 patients post-standard treatment, which is expected to significantly increase participant numbers and enhance the reliability of study outcomes.
- Price Target Increase: Truist raised Nuvation Bio's price target from $11 to $13 on January 27 while maintaining a Buy rating, reflecting strong market expectations for its Ibtrozi product line despite seasonal challenges.
- Diverse R&D Pipeline: Nuvation Bio is advancing several clinical-stage candidates, including a BET inhibitor and a ROS1 inhibitor, demonstrating its diversified strategy in oncology aimed at filling market gaps and enhancing the company's competitive edge.
See More
Nvidia and Other Stocks Price Target Analysis
- Nvidia Stock Rise: Nvidia shares rose about 1% this morning following a strong quarterly performance and even stronger guidance, indicating its potential in universal architecture is greater than previously thought, which may attract more investor interest.
- Price Target Increases: JPMorgan raised Nvidia's price target from $250 to $265, implying about a 36% upside, while Morgan Stanley maintained a $260 target despite concerns over its largest customers' cash flows, indicating strong underlying compute demand.
- Salesforce Performance Drag: Salesforce's numbers are negatively impacted by weakness in legacy applications like marketing and Tableau, and although Agentforce reached $800 million in annual recurring revenue, it has not yet compensated for the overall performance shortfall, highlighting challenges in the SaaS market.
- Qnity Electronics Strong Performance: Qnity Electronics exceeded market expectations with a strong fourth-quarter performance and 2026 guidance, announcing a $500 million buyback, leading to an 8.5% rise in shares this morning, reflecting market confidence in its future growth.
See More
Latest Wall Street Rating Updates
- Nvidia Rating Reaffirmed: Bank of America raised its price target on Nvidia to $300 from $275, highlighting its transformation from a traditional PC graphics chip vendor to a supplier for high-end gaming, enterprise graphics, and cloud markets, indicating strong market potential.
- Snowflake Rating Maintained: Morgan Stanley lowered its price target on Snowflake to $245 but maintained an overweight rating, reflecting confidence in a healthy demand environment, particularly following the company's fourth-quarter performance.
- Salesforce Price Target Cut: JPMorgan reduced its price target on Salesforce from $365 to $320, emphasizing its leading position in cloud computing and multi-product success story, despite facing market challenges.
- Alcon Upgraded to Overweight: Wells Fargo upgraded Alcon from equal weight to overweight, anticipating growth driven by a new product cycle, raising its price target to $97, which reflects an optimistic outlook on future performance.
See More
Truist Initiates Buy Rating on Toll Brothers with $190 Price Target
- Investment Rating Upgrade: Truist has initiated a buy rating on Toll Brothers with a $190 price target, indicating a 24% upside, reflecting strong market confidence in the company.
- Market Positioning Advantage: Analysts highlight that Toll Brothers' focus on the luxury home market differentiates it from competitors, and its higher price point has helped it achieve category leader status, suggesting continued stable performance.
- Future Growth Potential: Analysts believe that Toll Brothers will benefit from a rebound in the luxury home market in 2027, and its limited competition compared to low-end builders showcases its unique position in the market.
- Strong Stock Performance: Toll Brothers' shares have risen 14% this year and 42% over the past 12 months, indicating investor recognition of its long-term growth potential, especially amid the structural undersupply of homes in the U.S.
See More
BeOne Medicines AG Raises 2026 Revenue Guidance Amid Strong Q4 Results
- Significant Revenue Growth: BeOne Medicines AG reported global revenues of $1.5 billion for Q4 2025, reflecting a 33% increase from the previous quarter, while projecting $5.3 billion for 2026, a 40% year-over-year growth, indicating strong market performance and growth potential.
- Strong Brukinsa Performance: The company's lymphoma and leukemia treatment, Brukinsa, generated revenues of $1.1 billion and $3.9 billion for Q4 and the full year, respectively, marking increases of 38% and 49% from prior periods, further solidifying its market position in oncology.
- Analyst Price Target Increase: On February 27, Truist Securities raised its price target for BeOne Medicines AG from $400 to $412 while maintaining a Buy rating, reflecting confidence in the company's future growth, especially following the release of its fiscal 2026 revenue guidance.
- Market Expectation Pressure: Although the fiscal 2026 revenue guidance ranges from $6.2 billion to $6.4 billion, closely aligning with consensus estimates of $6.4 billion, analysts noted that this expectation has added pressure on the stock price, indicating a cautious market outlook on the company's future growth.
See More
Centene Named Among 14 Best GARP Stocks by Analysts
- Target Price Increase: Truist raised Centene's price target from $47 to $49 while maintaining a Buy rating, indicating analysts' optimism about the company's future growth, particularly after positive management meetings that highlighted confidence in profitability across various segments.
- Earnings Performance: In the Q4 2025 earnings report, Centene reported an adjusted diluted loss per share of $1.19; however, CEO Sarah London noted that the company slightly exceeded expectations shared in the third quarter, demonstrating resilience during a challenging year.
- Market Outlook: London anticipates that adjusted EPS for 2026 will exceed $3, representing over 40% year-over-year growth, which not only reflects stability in Medicaid and Marketplace segments but also indicates a rebuilding of the company's earnings strength.
- Business Diversification: Centene focuses on providing integrated services to government-sponsored and commercial healthcare programs, particularly for underinsured and uninsured individuals, with its diversified business model offering strong support for future growth.
See More
Nuvation Bio Expands SIGMA Study to Phase 3 Trial
- Clinical Trial Expansion: On February 9, Nuvation Bio announced a protocol amendment to the global SIGMA study, expanding it to a Phase 3 trial aimed at evaluating the efficacy of safusidenib for high-risk IDH1-mutant astrocytoma patients, highlighting the company's potential in oncology treatment.
- Expanded Patient Eligibility: The new protocol broadens patient eligibility in the registrational trial to include grades 2 and 3 IDH1-mutant astrocytoma patients with high-risk features, as well as grade 4 patients post-standard treatment, which is expected to significantly increase participant numbers and enhance the reliability of study outcomes.
- Price Target Increase: Truist raised Nuvation Bio's price target from $11 to $13 on January 27 while maintaining a Buy rating, reflecting strong market expectations for its Ibtrozi product line despite seasonal challenges.
- Diverse R&D Pipeline: Nuvation Bio is advancing several clinical-stage candidates, including a BET inhibitor and a ROS1 inhibitor, demonstrating its diversified strategy in oncology aimed at filling market gaps and enhancing the company's competitive edge.
See More
Nvidia and Other Stocks Price Target Analysis
- Nvidia Stock Rise: Nvidia shares rose about 1% this morning following a strong quarterly performance and even stronger guidance, indicating its potential in universal architecture is greater than previously thought, which may attract more investor interest.
- Price Target Increases: JPMorgan raised Nvidia's price target from $250 to $265, implying about a 36% upside, while Morgan Stanley maintained a $260 target despite concerns over its largest customers' cash flows, indicating strong underlying compute demand.
- Salesforce Performance Drag: Salesforce's numbers are negatively impacted by weakness in legacy applications like marketing and Tableau, and although Agentforce reached $800 million in annual recurring revenue, it has not yet compensated for the overall performance shortfall, highlighting challenges in the SaaS market.
- Qnity Electronics Strong Performance: Qnity Electronics exceeded market expectations with a strong fourth-quarter performance and 2026 guidance, announcing a $500 million buyback, leading to an 8.5% rise in shares this morning, reflecting market confidence in its future growth.
See More
Latest Wall Street Rating Updates
- Nvidia Rating Reaffirmed: Bank of America raised its price target on Nvidia to $300 from $275, highlighting its transformation from a traditional PC graphics chip vendor to a supplier for high-end gaming, enterprise graphics, and cloud markets, indicating strong market potential.
- Snowflake Rating Maintained: Morgan Stanley lowered its price target on Snowflake to $245 but maintained an overweight rating, reflecting confidence in a healthy demand environment, particularly following the company's fourth-quarter performance.
- Salesforce Price Target Cut: JPMorgan reduced its price target on Salesforce from $365 to $320, emphasizing its leading position in cloud computing and multi-product success story, despite facing market challenges.
- Alcon Upgraded to Overweight: Wells Fargo upgraded Alcon from equal weight to overweight, anticipating growth driven by a new product cycle, raising its price target to $97, which reflects an optimistic outlook on future performance.
See More
